← Back to Clinical Trials
Recruiting NCT05892952

NCT05892952 IONA Longitudinal Cohort Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05892952
Status Recruiting
Phase
Sponsor Brain Health Scotland Life Sciences Ltd
Condition Alzheimer Disease
Study Type OBSERVATIONAL
Enrollment 10,000 participants
Start Date 2023-12-21
Primary Completion 2033-12-21

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 120 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 10,000 participants in total. It began in 2023-12-21 with a primary completion date of 2033-12-21.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Understanding more about how diseases that cause dementia develop is critical as the number of people living with, or affected by, dementia in Scotland continues to grow. The IONA Longitudinal Cohort Study (LCS) has been set up to gather information about people's cognitive health (their memory and thinking abilities), their lifestyle and health risk factors for future dementia (such as hearing loss and obesity), genetics and disease biomarkers, over a number of years. The IONA LCS has three main objectives: Firstly to develop this cohort that is well characterised (also known as being "well-phenotyped") that represent the Scottish population (taking into consideration age, sex, ethnicity and education). The second objective is to use this data to build disease models to better understand trajectories of diseases, and identify any sub-populations who have different (i.e. better, worse) disease trajectories. Finally the third objective for IONA LCS is to offer people an optional consent to hear about future studies they may be interested in taking part in.

Eligibility Criteria

* Age at least 50 years. * Living in Scotland. * Able to read and write and with minimum 7 years of formal education. * Have a study partner who is aged 18 years or older. * Have capacity to provide informed consent at baseline. * Able to speak English to a level where the cognitive assessments can be completed.

Contact & Investigator

Central Contact

Sarah Gregory, PhD

✉ s.gregory@brainsciences.scot

📞 0131 353 0233

Frequently Asked Questions

Who can join the NCT05892952 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 120 Years, studying Alzheimer Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05892952 currently recruiting?

Yes, NCT05892952 is actively recruiting participants. Contact the research team at s.gregory@brainsciences.scot for enrollment information.

Where is the NCT05892952 trial being conducted?

This trial is being conducted at Edinburgh, United Kingdom.

Who is sponsoring the NCT05892952 clinical trial?

NCT05892952 is sponsored by Brain Health Scotland Life Sciences Ltd. The trial plans to enroll 10,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology